Zyprexa

Federal Drug Administration to treat moderate to severe Alzheimer's by reducing activity of the brain chemical glutamate.

Preliminary studies have also shown that cholesterol medications, such as Lipitor and Zocor, which are taken to reduce cholesterol levels, may actually have some benefits in delaying the onset of Alzheimer's.

With further proof, I will be prescribing these medications as well.

While there is still no permanent cure, it is vital to take preventative measures as we enter our golden years.

We should be maintaining low cholesterol levels while increasing our intake of folic acid, as well as keeping up physical exercise.

Social activities - and not isolating - and keeping our brains sharp by doing crossword puzzles, playing bridge and reading more are all critical to living healthy, productive lives as we age.

For more information visit www.alzheimers.org," www.alz.org or www.eldercare.gov" or www.eldercare.gov.

Dr.

Dileep Kumar specializes in internal medicine and is a member of Sutter Delta Medical Group Affiliate of Sutter Regional Medical Foundation.

email this print this News About the R...

The ranks of the formerly uninsured include very destitute patients who weren't getting the meds they needed in the past.

"Overall, though, Big Pharma won't be happy with Medicare Part D's outcome, a situation that could worsen for them if Democrats do well in next November's midterm Congressional elections.

SAVE What is this?

Special Offer: TERMS UNDER WHICH ...

“Lilly has been more innovative than most other companies but done worse at execution,” said Barbara Ryan an analyst at Deutsche Bank.

“There’s betting on a pipeline that hasn’t panned out in the past.” In each of the last four years, analysts earnings projections fell through the 12 months, according to Zacks, reflecting negative developments or sentiment.

“The company is not without controversy,” said Schott.

Yet, he is willing to trust Lilly because he likes the management and the strategy.

Born in Morocco and fluent in four languages, Taurel is a favorite among analysts for his direct but personable style.

Taurel acknowledged some products’ performance has been disappointing, most notably Xigris, an expensive biotech drug against sepsis which is only effective in a limited population.

“We had so many new products in a short time that maybe we didn’t do the best job with each,” Taurel concedes.

Taurel said he was dismayed by the slowdown in Cymbalta prescriptions but has taken steps to boo...